Xanadu Bio
Gladwyne
About Xanadu Bio
Xanadu Bio is a privately-held nanoparticle delivery company focusing on the delivery of mRNA and other nucleic acids that uses PACE platform technology. The company develops an intranasal SARS-CoV-2 vaccine booster, after systemic vaccination, to protect against infection in the nasosinusal/upper airways, thus potentially reducing SARS-CoV-2 transmission in the community.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $22.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2025)
- Website: xanadubio.com
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/xanadu-bio-38503 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.